newsfilter
← Latest News
GlobeNewswire·

Tvardi Therapeutics to Host KOL Webinar on the Clinical Potential of TTI-109 in Ulcerative Colitis (UC) and the Evolving Treatment Landscape, on August 19, 2026

  • Tvardi Therapeutics will host a Key Opinion Leader webinar on August 19, 2026, at 11:00 AM ET featuring Dr. Randy Longman from Weill Cornell Medicine.
  • The event will discuss the ulcerative colitis treatment landscape, unmet needs, the scientific rationale for targeting STAT3, & new Phase 1 healthy volunteer data for TTI-109.
  • Management will present the planned clinical development strategy for TTI-109, including potential integration into the UC treatment paradigm.
  • Tvardi plans to initiate a Phase 1 clinical trial for TTI-109 in patients with moderate-to-severe ulcerative colitis in 2027, subject to IND clearance & additional funding.
  • The primary endpoint of the planned UC trial is safety, with clinical remission at 12 weeks as the secondary endpoint.
  • Exploratory endpoints will include serum/tissue biomarkers & analysis of single nucleotide polymorphisms (SNPs).
  • Tvardi is currently conducting a Phase 1b/2 clinical trial of TTI-101 in hepatocellular carcinoma (NCT05440708).
  • The webinar & replay will be accessible via the "Events and Presentations" page under the "Investors" section of the Tvardi website.